[go: up one dir, main page]

NO20010203L - Diacylhydrazinderivater som integrininhibitorer - Google Patents

Diacylhydrazinderivater som integrininhibitorer

Info

Publication number
NO20010203L
NO20010203L NO20010203A NO20010203A NO20010203L NO 20010203 L NO20010203 L NO 20010203L NO 20010203 A NO20010203 A NO 20010203A NO 20010203 A NO20010203 A NO 20010203A NO 20010203 L NO20010203 L NO 20010203L
Authority
NO
Norway
Prior art keywords
integrin inhibitors
diacylhydrazine derivatives
diacylhydrazine
derivatives
arteriosclerosis
Prior art date
Application number
NO20010203A
Other languages
English (en)
Other versions
NO20010203D0 (no
Inventor
Guenter Hoelzemann
Simon Goodman
Horst Kessler
Christoph Gibson
Joerg Simon Schmitt
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of NO20010203D0 publication Critical patent/NO20010203D0/no
Publication of NO20010203L publication Critical patent/NO20010203L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
    • C07D271/113—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C281/00—Derivatives of carbonic acid containing functional groups covered by groups C07C269/00 - C07C279/00 in which at least one nitrogen atom of these functional groups is further bound to another nitrogen atom not being part of a nitro or nitroso group
    • C07C281/06—Compounds containing any of the groups, e.g. semicarbazides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30—Nitrogen atoms not forming part of a nitro radical

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Forbindelser med formel (I) '' ? f yyvv* hvor X, Y, Z, R1 og R2 har de i krav l angitte betydninger, samt deres salter og solvater, kan anvendes som integrin- inhibitorer, særlig til profylakse og behandling av sykdommer i blodomløpet, ved trombose, hjerteinfarkt, koronare hjertesykdommer, arteriosklerose, ved patologiske hendelser som underholdes eller propageres gjennom angiogenese, og innen tumorterapien.
NO20010203A 1998-07-15 2001-01-12 Diacylhydrazinderivater som integrininhibitorer NO20010203L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19831710A DE19831710A1 (de) 1998-07-15 1998-07-15 Diacylhydrazinderivate
PCT/EP1999/004673 WO2000003973A1 (de) 1998-07-15 1999-07-06 Diacylhydrazinderivate als integrin-inhibitoren

Publications (2)

Publication Number Publication Date
NO20010203D0 NO20010203D0 (no) 2001-01-12
NO20010203L true NO20010203L (no) 2001-01-12

Family

ID=7874107

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20010203A NO20010203L (no) 1998-07-15 2001-01-12 Diacylhydrazinderivater som integrininhibitorer

Country Status (22)

Country Link
US (1) US6326403B1 (no)
EP (1) EP1097127B1 (no)
JP (1) JP2002520382A (no)
KR (1) KR20010079520A (no)
CN (1) CN1309633A (no)
AR (1) AR019777A1 (no)
AT (1) ATE234276T1 (no)
AU (1) AU753333B2 (no)
BR (1) BR9912072A (no)
CA (1) CA2337305A1 (no)
DE (2) DE19831710A1 (no)
DK (1) DK1097127T3 (no)
ES (1) ES2194486T3 (no)
HU (1) HUP0102602A3 (no)
ID (1) ID27168A (no)
NO (1) NO20010203L (no)
PL (1) PL345398A1 (no)
PT (1) PT1097127E (no)
SK (1) SK412001A3 (no)
TW (1) TW448145B (no)
WO (1) WO2000003973A1 (no)
ZA (1) ZA200101267B (no)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ300710B6 (cs) 1999-06-01 2009-07-22 Biogen Idec Ma Inc. Použití blokující monoklonální protilátky proti VLA-1 pro výrobu farmaceutického prípravku k lécení zánetlivých onemocnení
UY26664A1 (es) * 2000-04-14 2001-11-30 Abbott Lab Hidrazidas y alcoxiamidas inhibidoras de la angiogénesis.
US20020002152A1 (en) 2000-04-14 2002-01-03 Craig Richard A. Hydrazide and alkoxyamide angiogenesis inhibitors
DE10040105A1 (de) 2000-08-17 2002-02-28 Merck Patent Gmbh Peptid- und Peptidmimetika-Derivate mit Integrin-Inhibitor-Eigenschaften
DE10040103A1 (de) 2000-08-17 2002-02-28 Merck Patent Gmbh Peptid- und Peptidmimetika-Derivate mit Integrin-Inhibitor-Eigenschaften II
DZ3415A1 (fr) * 2000-08-31 2002-03-07 Chiron Corp Guanidinobenzamides comme mc4-r agonistes.
DK1385823T3 (da) 2001-04-09 2007-03-26 Novartis Vaccines & Diagnostic Guanidinoforbindelser som melanocortin-4-receptor- (MC4-R) -agonister
UA83791C2 (ru) 2001-04-13 2008-08-26 Байоджен Айдек Ма Инк. Антитело против vla-1, фармацевтическая композиция, которая его содержит, и из применение для лечения индивидуума с иммунологическим расстройством, опосредованным vla-1
DE60333937D1 (de) 2002-05-23 2010-10-07 Novartis Vaccines & Diagnostic Substituierte quinazolinone verbindungen
US7226577B2 (en) 2003-01-13 2007-06-05 Bracco Imaging, S. P. A. Gastrin releasing peptide compounds
US7304161B2 (en) * 2003-02-10 2007-12-04 Intrexon Corporation Diaclhydrazine ligands for modulating the expression of exogenous genes in mammalian systems via an ecdysone receptor complex
US7456315B2 (en) 2003-02-28 2008-11-25 Intrexon Corporation Bioavailable diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex
WO2004112793A1 (en) 2003-05-23 2004-12-29 Chiron Corporation Guanidino-substituted quinazolinone compounds as mc4-r agonists
DE10325049A1 (de) * 2003-06-02 2004-12-23 Merck Patent Gmbh Peptid- und Peptidmimetika-Derivate mit Integrin-Inhibitor-Eigenschaften III
AU2004293012A1 (en) 2003-11-19 2005-06-09 Rustum S. Boyce Quinazolinone compounds with reduced bioaccumulation
PL1765362T3 (pl) 2004-06-04 2012-08-31 Scripps Research Inst Kompozycje i sposoby do leczenia chorób związanych z neowaskularyzacją
JP4745175B2 (ja) * 2005-12-28 2011-08-10 本田技研工業株式会社 自動二輪車
US10119979B2 (en) 2006-05-25 2018-11-06 Biogen Ma Inc. Methods of treating stroke and traumatic brain injury using humanized AQC2 anti-VLA-1 antibodies
RU2490253C2 (ru) 2007-05-29 2013-08-20 Интрексон Корпорейшн Хиральные диацилгидразиновые лиганды для модуляции экспрессии экзогенных генов с помощью экдизон-рецепторного комплекса
NZ629204A (en) 2012-02-16 2016-09-30 Santarus Inc Anti-vla1 (cd49a) antibody pharmaceutical compositions
NZ712167A (en) 2013-03-15 2018-05-25 Intrexon Corp Boron-containing diacylhydrazines
JP6649902B2 (ja) 2014-05-30 2020-02-19 ファイザー・インク 選択的アンドロゲン受容体モジュレーターとしてのカルボニトリル誘導体
CN104027805B (zh) * 2014-06-18 2017-02-15 北京大学 抑制整合素α5的物质在制备预防内皮细胞激活和/或动脉粥样硬化的产品中的新用途
US9944659B2 (en) 2014-09-17 2018-04-17 Intrexon Corporation Boron-containing diacylhydrazine compounds
JP7445594B2 (ja) 2017-11-01 2024-03-07 アローヘッド ファーマシューティカルズ インコーポレイテッド インテグリンリガンドおよびその使用
AU2022254705A1 (en) 2021-04-08 2023-10-05 Arrowhead Pharmaceuticals, Inc. Rnai agents for inhibiting expression of receptor for advanced glycation end-products, compositions thereof, and methods of use
WO2023275715A1 (en) 2021-06-30 2023-01-05 Pfizer Inc. Metabolites of selective androgen receptor modulators

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5051405A (en) * 1989-10-10 1991-09-24 Rhone-Poulenc Rorer Pharmaceuticals Inc. Anti-thrombotic peptides and pseudopeptides
WO1992013552A1 (en) * 1991-02-05 1992-08-20 Smithkline Beecham Corporation Anti-aggregatory peptides containing an aromatic ester or amide
US5530028A (en) * 1992-11-23 1996-06-25 Rohm And Haas Company Insecticidal N'-substituted-N,N'-diacylhydrazines
US5726192A (en) * 1992-12-29 1998-03-10 Smithkline Beecham Corporation Platelet aggregation inhibiting compounds
ES2186720T3 (es) 1994-05-27 2003-05-16 Merck & Co Inc Composiciones para inhibir la reabsorcion osea mediada por osteoclastos.
US5482962A (en) * 1994-07-22 1996-01-09 Rohm And Haas Company Insecticidal N,N'-disubstituted-N-N'-diacylhydrazines
AU713676B2 (en) * 1996-01-16 1999-12-09 Merck & Co., Inc. Integrin receptor antagonists

Also Published As

Publication number Publication date
EP1097127A1 (de) 2001-05-09
EP1097127B1 (de) 2003-03-12
NO20010203D0 (no) 2001-01-12
ZA200101267B (en) 2002-10-04
AU5031399A (en) 2000-02-07
PT1097127E (pt) 2003-07-31
CN1309633A (zh) 2001-08-22
ID27168A (id) 2001-03-08
PL345398A1 (en) 2001-12-17
TW448145B (en) 2001-08-01
US6326403B1 (en) 2001-12-04
CA2337305A1 (en) 2000-01-27
DE19831710A1 (de) 2000-01-20
JP2002520382A (ja) 2002-07-09
DE59904547D1 (de) 2003-04-17
HUP0102602A3 (en) 2002-02-28
KR20010079520A (ko) 2001-08-22
ATE234276T1 (de) 2003-03-15
ES2194486T3 (es) 2003-11-16
AR019777A1 (es) 2002-03-13
WO2000003973A1 (de) 2000-01-27
AU753333B2 (en) 2002-10-17
BR9912072A (pt) 2001-09-25
HUP0102602A2 (hu) 2002-01-28
DK1097127T3 (da) 2003-06-10
SK412001A3 (en) 2001-08-06

Similar Documents

Publication Publication Date Title
NO20010203L (no) Diacylhydrazinderivater som integrininhibitorer
NO986090L (no) Fenylalaninderivater som integrininhibitorer
TW372232B (en) Phenylalanine derivatives
NO992821L (no) Ketobenzamider som calpain-inhibitorer
NO20021328L (no) Pyrazolopyrimidier som terapeutiske midler
CA2280727A1 (en) Bicyclic amino acids
WO2000071516A3 (en) INHIBITORS OF FACTOR Xa
WO2000071493A3 (en) INHIBITORS OF FACTOR Xa
EA200000723A1 (ru) Производные 2-(пурин-9-ил)-тетрагидрофуран-3,4-диола
NO20060971L (no) Pyridazinderivater og deres anvendelse som terapeutiske midler
NO961841L (no) Antitrombotiske amidinofenylalanin- og amidinopyridylalaninderivater
FI913478A0 (fi) Diazinderivat.
ATE396174T1 (de) Hydroxyalkylaminderivate als beta-secretase- inhibitoren und deren verwendung zur behandlung der alzheimerschen krankheit oder ähnlicher krankheiten
NO991761L (no) Nye piperidin-kotokarbonsyre-derivater, deres fremstilling og anvendelse
DK1107973T3 (da) Hidtil ukendte thieno(2,3-D)pyrimidindioner, fremgangsmåde til deres fremstilling og anvendelse deraf i terapi
DE60221505D1 (de) FAKTOR Xa BENZAMIDIN INHIBITOREN
NO20016201L (no) Tienopyrimidiner som fosfodiesteraseinhibitorer
CA2348391A1 (en) Chromenone and chromanone derivatives as integrin inhibitors
WO2000048996A3 (de) Beta-alaninderivate
WO2003059258A3 (en) Compositions and methods for treating heart failure
MY133785A (en) Azabicyclooctane derivatives useful in the treatment of cardiac arrhythmias
WO1996040743A3 (en) Inhibitors of factor xa
WO2003059265A3 (en) Compositions and methods for treating heart failure
NO20000016L (no) Sykliske azapeptider med angiogen virkning
ES2088128T3 (es) Aminosulfonilureas inhibidoras de acat.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application